Paul M Kaye (Paul Kaye)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 22

Top Venues

Wellcome open research

PLoS neglected tropical diseases

PloS one

Nature communications

University of York

University College London (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of York Oct 01 2004

United Kingdom

Professor of Immunology :: Hull York Medical School

London School of Hygiene and Tropical Medicine Jan 01 1985 - Sep 30 2004

United Kingdom

Professor of Cellular Immunology :: Infectious and Tropical Diseases

Education History

University College London Oct 01 1981 - Dec 31 1984

United Kingdom

PHD :: ICRF Tumor Immunology Unit

Publications

Vivak Parkash, Helen Ashwin, Shoumit Dey, Jovana Sadlova, Barbora Vojtkova, Katrien Van Bocxlaer, Rebecca Wiggins, David Thompson, Nidhi Sharma Dey, Charles L Jaffe, Eli Schwartz, Petr Volf, Charles J N Lacey, Alison Margaret Layton, Paul M Kaye
Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis. Nature medicine (2024)
Helen Ashwin, Luke Milross, Julie Wilson, Joaquim Majo, Jimmy Tsz Hang Lee, Grant Calder, Bethany Hunter, Sally James, Dimitris Lagos, Nathalie Signoret, Andrew Filby, Omer Ali Bayraktar, Andrew J Fisher, Paul M Kaye
Identification of a protein expression signature distinguishing early from organising diffuse alveolar damage in COVID-19 patients. Journal of clinical pathology (2023)
Sakshi Mohan, Paul Revill, Stefano Malvolti, Melissa Malhame, Mark J Sculpher, Paul M Kaye
Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates. PLoS neglected tropical diseases 16 (6) (2022)
Charles J Lacey, Ahmed Musa, El Tahir Khalil, Brima Younis, Mohamed Osman, Rebecca Wiggins, Ada Keding, Paul M Kaye
LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis. Wellcome open research 7 (2022)
Malcolm S Duthie, Bruna A S Machado, Roberto Badaró, Paul M Kaye, Steven G Reed
Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs. Pathogens (Basel, Switzerland) 11 (11) (2022)
Stefano Malvolti, Melissa Malhame, Carsten F Mantel, Epke A Le Rutte, Paul M Kaye
Human leishmaniasis vaccines: Use cases, target population and potential global demand. PLoS neglected tropical diseases 15 (9) (2021)
Vivak Parkash, Helen Ashwin, Jovana Sadlova, Barbora Vojtkova, Georgina Jones, Nina Martin, Elizabeth Greensted, Victoria Allgar, Shaden Kamhawi, Jesus G Valenzuela, Alison M Layton, Charles L Jaffe, Petr Volf, Paul M Kaye, Charles J N Lacey
A clinical study to optimise a sand fly biting protocol for use in a controlled human infection model of cutaneous leishmaniasis (the FLYBITE study). Wellcome open research 6 (2021)
Helen Ashwin, Jovana Sadlova, Barbora Vojtkova, Tomas Becvar, Patrick Lypaczewski, Eli Schwartz, Elizabeth Greensted, Katrien Van Bocxlaer, Marion Pasin, Kai S Lipinski, Vivak Parkash, Greg Matlashewski, Alison M Layton, Charles J Lacey, Charles L Jaffe, Petr Volf, Paul M Kaye
Characterization of a new Leishmania major strain for use in a controlled human infection model. Nature communications 12 (1) (2021)
Paul M Kaye, Sakshi Mohan, Carsten Mantel, Melissa Malhame, Paul Revill, Epke Le Rutte, Vivak Parkash, Alison M Layton, Charles J N Lacey, Stefano Malvolti
Overcoming roadblocks in the development of vaccines for leishmaniasis. Expert review of vaccines (2021)
Gulab Fatima Rani, Helen Ashwin, Najmeeyah Brown, Ian S Hitchcock, Paul M Kaye
Hematological consequences of malaria infection in mice previously treated for visceral leishmaniasis. Wellcome open research 6 (2021)
Rachel C Findlay, Mohamed Osman, Kirstin A Spence, Paul M Kaye, Pegine B Walrad, Laurence G Wilson
High-speed, three-dimensional imaging reveals chemotactic behaviour specific to human-infective Leishmania parasites. eLife 10 (2021)
Gulab Fatima Rani, Helen Ashwin, Najmeeyah Brown, Ian S Hitchcock, Paul M Kaye
Hematological consequences of malaria in mice previously treated for visceral leishmaniasis. Wellcome open research 6 (2021)
James P Hewitson, Katie A West, Kylie Renee James, Gulab Fatima Rani, Nidhi Sharma Dey, Audrey Romano, Najmeeyah Brown, Sarah A Teichmann, Paul M Kaye, Dimitris Lagos
Malat1 Suppresses Immunity to Infection through Promoting Expression of Maf and IL-10 in Th Cells. Journal of immunology (Baltimore, Md. : 1950) 204 (11) (2020)
Sarah Forrester, Karin Siefert, Helen Ashwin, Najmeeyah Brown, Andrea Zelmer, Sally James, Dimitris Lagos, Jon Timmis, Mitali Chatterjee, Jeremy Charles Mottram, Simon L Croft, Paul M Kaye
Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis. Wellcome open research 4 (2019)
Malini Pires, Barry Wright, Paul M Kaye, Virgínia da Conceição, Rachel C Churchill
The impact of leishmaniasis on mental health and psychosocial well-being: A systematic review. PloS one 14 (10) (2019)
Helen Ashwin, Karin Seifert, Sarah Forrester, Najmeeyah Brown, Sandy MacDonald, Sally James, Dimitris Lagos, Jon Timmis, Jeremy Charles Mottram, Simon L Croft, Paul M Kaye
Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis. Wellcome open research 3 (2019)
Helen Ashwin, Karin Seifert, Sarah Forrester, Najmeeyah Brown, Sandy MacDonald, Sally James, Dimitris Lagos, Jon Timmis, Jeremy Charles Mottram, Simon L Croft, Paul M Kaye
Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis. Wellcome open research (2019)
James P Hewitson, Kunal M Shah, Najmeeyah Brown, Paul Grevitt, Sofia Hain, Katherine Newling, Tyson V Sharp, Paul M Kaye, Dimitris Lagos
miR-132 suppresses transcription of ribosomal proteins to promote protective Th1 immunity. EMBO reports 20 (4) (2019)
Mohamed Osman, Anoop Mistry, Ada Keding, Rhian Gabe, Elizabeth Cook, Sarah Forrester, Rebecca Wiggins, Stefania Di Marco, Stefano Colloca, Loredana Siani, Riccardo Cortese, Deborah F Smith, Toni Aebischer, Paul M Kaye, Charles J Lacey
A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. PLoS neglected tropical diseases 11 (5) (2017)
Ana Isabel Pinto, Najmeeyah Brown, Olivier Preham, Johannes S P Doehl, Helen Ashwin, Paul M Kaye
TNF signalling drives expansion of bone marrow CD4+ T cells responsible for HSC exhaustion in experimental visceral leishmaniasis. PLoS pathogens 13 (7) (2017)
Johannes S P Doehl, Zoe Bright, Shoumit Dey, Helen Davies, John Magson, Najmeeyah Brown, Audrey Romano, Jane E Dalton, Ana I Pinto, Jon W Pitchford, Paul M Kaye
Skin parasite landscape determines host infectiousness in visceral leishmaniasis. Nature communications 8 (1) (2017)
John W J Moore, Lynette Beattie, Mohamed Osman, Benjamin M J Owens, Najmeeyah Brown, Jane E Dalton, Asher Maroof, Paul M Kaye
CD4+ Recent Thymic Emigrants Are Recruited into Granulomas during Leishmania donovani Infection but Have Limited Capacity for Cytokine Production. PloS one 11 (9) (2016)

Paul M Kaye.css-eqlu8i{font-size:small;padding-left:4px;} (Paul Kaye)

Publication Activity (10 Years)

Top Topics

Top Venues

Paul M Kaye (Paul Kaye)